Edoxaban concentration in Thai patients with nonvalvular atrial fibrillation: real world study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20250905001

Enrollment

154

Registered

2025-09-05

Start date

2025-07-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Edoxaban Plasma Concentration in Thai Nonvalvular Atrial Fibrillation (NVAF) Edoxaban, Atrial Fibrillation, Anticoagulants, Pharmacokinetics, Drug Concentration, Thailand, Real-World Evidence

Interventions

non valvular AF on edoxaban

Other

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Thai non-valular AF aged 18 years or older. - Who have been receiving edoxaban with 100% adherence for at least 7 days. - Who provide informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: - Moderate to severe mitral valve stenosis or mechanical heart valve replacement. - Pregnant or breastfeeding volunteers. - Psychiatric disorders or dementia without a caregiver to manage their medication.

Design outcomes

Primary

Measure	Time frame
efficacy at 1 year Stroke or systemic embolism (SSE),efficacy at 1 year stroke,safety 1 year major bleeding,safety 1 year any bleeding	—

Secondary

Measure	Time frame
safety 1 year minor bleeding	—

Countries

Thailand

Contacts

Public ContactSudchaya Prasoetpan

Nopparat Rajathanee Hospital

sudchaya.pra@gmail.com0839552451

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026